title: Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis.
abstract: Akinetic crisis (AC) is a much-feared complication of Parkinson's disease (PD) which may appear upon abrupt cessation or malabsorption of dopaminergic medication due to gastrointestinal tract disorders or acute surgery. Intravenous infusion of amantadine sulphate or subcutaneous administration of apomorphine are established treatment strategies for AC. We speculate whether the use of a non-invasive transdermal application form (patch) of a dopaminergic drug (rotigotine) may represent a useful alternative treatment option. We describe the successful treatment of severe AC using rotigotine in a PD patient with gastro-oesophageal ulcers which precluded administration of any oral medication. This case demonstrates that a rotigotine patch might be effective in the treatment of AC. We suggest that rotigotine may represent a useful treatment option due to its favourable receptor profile and unique application form. In particular, it may be helpful in situations that might provoke AC, such as acute surgery. However, experience of the use of the rotigotine patch in this clinical setting is rather sparse and the patch is currently not approved for this indication.
authors.affiliation: Institute of Neuroscience and Biophysics - Medicine, Research Centre Jülich, Leo-Brandt-Str. 1, D-52428 Jülich, Germany. m.dafotakis@fz-juelich.de
authors.forename: Manuel
authors.initials: M
authors.lastname: Dafotakis
authors.forename: Roland
authors.initials: R
authors.lastname: Sparing
authors.forename: Agnes
authors.initials: A
authors.lastname: Juzek
authors.forename: Frank
authors.initials: F
authors.lastname: Block
authors.forename: Christoph M
authors.initials: CM
authors.lastname: Kosinski
mesh_terms: D000279:Administration, Cutaneous; D018491:Dopamine Agonists / Q000008:administration & dosage*; D005239:Fear; D006801:Humans; D008286:Malabsorption Syndromes / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000150:complications / Q000523:psychology; D012720:Severity of Illness Index; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*
chemical_list: D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine